Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3549017 | 0.92 | AKR1C1 (0.40) | AKR1C1MEN1KMT2ANPSR1 | |
| SCHEMBL27142106 | 0.75 | AKR1C1 (0.41) | AKR1C1CYP3A4MAPK1CYP2C19MEN1 | |
| SCHEMBL3542721 | 0.74 | CYP3A4 (0.38) | CYP3A4MAPK1CYP2C19MEN1KMT2A | |
| SCHEMBL3550933 | 0.71 | SMN1; SMN2 (0.46) | MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL7261346 | 0.71 | L3MBTL1 (0.35) | KMT2ATSHRSMN1; SMN2ALDH1A1HSD17B10 | |
| SCHEMBL22201 | 0.69 | — | — | |
| SCHEMBL31117363 | 0.68 | CTSK (0.44) | AKR1C1CYP3A4MAPK1CYP2C19TSHR | |
| SCHEMBL3452541 | 0.68 | — | — | |
| SCHEMBL31117786 | 0.68 | CTSK (0.39) | AKR1C1CYP3A4MAPK1CYP2C19TSHR | |
| SCHEMBL26128678 | 0.68 | CXCL8 (0.42) | MEN1KMT2ASMN1; SMN2ALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2350022-B1 | NEW BENZIMIDAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2013-11-20 | — | — | EP | claimed |
| US-8143422-B2 | Benzimidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-03-27 | — | — | US | claimed |
| EP-2350022-A1 | NEW BENZIMIDAZOLE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2011-08-03 | — | — | EP | claimed |
| WO-2010043513-A1 | NEW BENZIMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-04-22 | — | — | WO | claimed |
| US-20100093818-A1 | BENZIMIDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2010-04-15 | — | — | US | claimed |
| EP-2350022-B1 | NEW BENZIMIDAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2013-11-20 | — | — | EP | disclosed |
| US-8143422-B2 | Benzimidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-03-27 | — | — | US | disclosed |
| EP-2350022-A1 | NEW BENZIMIDAZOLE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010043513-A1 | NEW BENZIMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-04-22 | — | — | WO | disclosed |
| US-20100093818-A1 | BENZIMIDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093818-A1 | BENZIMIDAZOLE DERIVATIVES | CYP2B6, CYP3A4, CYP2C19 | AKR1C1 268/4885CYP3A4 2/4885MAPK1 2808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.